Adverse events observed in patients during the trial period
| Event | Number of patients | Number of events |
| Total adverse events | 10 | 84 |
| Treatment-unrelated adverse events | 10 | 74 |
| Serious adverse event | 2 | 2 |
| HyperCKemia* | 1 | 1 |
| Gastritis | 1 | 1 |
| Mild to moderate adverse events | 10 | 72 |
| Common (occurred more than two patients) | ||
| Nasopharyngitis | 5 | 7 |
| Diarrhoea | 3 | 4 |
| Otalgia | 2 | 3 |
| Granulocytosis | 2 | 3 |
| Fever | 2 | 2 |
| Vomiting | 2 | 2 |
| Influenza | 2 | 2 |
| Crush | 2 | 2 |
| Leucocytosis | 2 | 2 |
| HyperCKemia | 2 | 2 |
| C-reactive protein elevation | 2 | 2 |
| Treatment-related adverse events | 6 | 10 |
| Serious adverse event | 0 | 0 |
| Mild to moderate adverse events | 6 | 10 |
| Diarrhoea | 1 | 1 |
| Constipation | 1 | 1 |
| Appetite loss | 1 | 1 |
| Insomnia | 1 | 1 |
| Oral aphtha | 1 | 1 |
| Reflux oesophagitis | 1 | 1 |
| γ-GTP elevation | 1 | 1 |
| Pollalkisuria | 1 | 1 |
| Hiatal hernia | 1 | 1 |
| Gastroenteritis | 1 | 1 |
*CK, creatine kinase.